UK markets close in 8 hours 9 minutes

Gain Therapeutics, Inc. (GANX)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
3.1900-0.2000 (-5.90%)
At close: 04:00PM EDT
3.2200 +0.03 (+0.94%)
After hours: 05:51PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 51.74M
Enterprise value 35.97M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)752.20
Price/book (mrq)4.11
Enterprise value/revenue 651.93
Enterprise value/EBITDA -1.62

Trading information

Stock price history

Beta (5Y monthly) 0.43
52-week change 3-35.56%
S&P500 52-week change 322.64%
52-week high 35.6500
52-week low 32.0000
50-day moving average 34.0546
200-day moving average 33.5248

Share statistics

Avg vol (3-month) 3162.57k
Avg vol (10-day) 386.21k
Shares outstanding 516.22M
Implied shares outstanding 616.22M
Float 814.26M
% held by insiders 116.45%
% held by institutions 111.79%
Shares short (28 Mar 2024) 4138.13k
Short ratio (28 Mar 2024) 40.94
Short % of float (28 Mar 2024) 40.91%
Short % of shares outstanding (28 Mar 2024) 40.85%
Shares short (prior month 29 Feb 2024) 4134.63k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-40,336.86%

Management effectiveness

Return on assets (ttm)-65.14%
Return on equity (ttm)-141.57%

Income statement

Revenue (ttm)55.18k
Revenue per share (ttm)0.00
Quarterly revenue growth (yoy)-100.00%
Gross profit (ttm)N/A
EBITDA -22.22M
Net income avi to common (ttm)-22.27M
Diluted EPS (ttm)-1.7100
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)16.79M
Total cash per share (mrq)1.03
Total debt (mrq)1.03M
Total debt/equity (mrq)8.17%
Current ratio (mrq)3.59
Book value per share (mrq)0.78

Cash flow statement

Operating cash flow (ttm)-18.87M
Levered free cash flow (ttm)-9.8M